SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced the appointment of Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Romano, based in the United States, brings over two decades of finance leadership experience in the medical technology and life sciences sectors. She will help lead the company’s financial operations as it advances its global expansion strategy, including pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
Most recently, Romano served as CFO of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet, and support strategic objectives. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, raising more than $100 million through public and private financings while overseeing strategic transactions, SEC reporting, and investor relations. According to the full press release, Romano’s appointment signals SS Innovations’ commitment to financial discipline and growth.
SS Innovations develops surgical robotic technologies with a vision to make robotic surgery affordable and accessible globally. The company’s product range includes the SSi Mantra surgical robotic system and the SSi Mudra suite of surgical instruments, which support various procedures, including cardiac surgery. Headquartered in India but incorporated in the U.S., SS Innovations plans to expand the global presence of its cost-effective surgical robotic solutions.
The company’s pursuit of FDA approval for the SSi Mantra system is a key milestone. As noted in the announcement, Romano’s experience in raising capital and managing financial operations will be critical in navigating the regulatory and commercial expansion phases. The appointment also comes as SS Innovations seeks to strengthen its balance sheet and reduce cash burn, leveraging Romano’s expertise from her tenure at Vicarious Surgical.
Forward-looking statements in the announcement highlight risks and uncertainties that could affect actual results, including factors outlined in the company’s SEC filings. Investors are cautioned not to rely unduly on these statements. For more details, the full terms of use and disclaimers are available on the InvestorBrandNetwork website.
